Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Leukemia

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 11187912
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia.

  2000cited by this paper
• Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report.

  2000cited by this paper
• Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia.

  2000cited by this paper
• Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group.

  2000cited by this paper
• Secondary neoplasms subsequent to Berlin-Frankfurt-Münster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy.

  2000cited by this paper
• Slow disappearance of peripheral blood blasts is an adverse prognostic factor in childhood T cell acute lymphoblastic leukemia: a Pediatric Oncology Group study

  2000cited by this paper
• Pharmacogenomics: translating functional genomics into rational therapeutics.

  1999cited by this paper
• Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: results of Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988-1991).

  1999cited by this paper
• Improved outcome for acute lymphoblastic leukemia in children of a developing country: results of the Chilean National Trial PINDA 87.

  1999cited by this paper
• Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.

  1999cited by this paper
• Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia.

  1999cited by this paper
• Prophylaxis and treatment of neoplastic meningeosis in childhood acute lymphoblastic leukemia

  1998cited by this paper
• Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro-vivo correlations and cross-resistance to other drugs.

  1998cited by this paper
• Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.

  1998cited by this paper
• Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica.

  1998cited by this paper
• Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.

  1998cited by this paper
• Philadelphia chromosome-positive (Ph+) childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome.

  1998cited by this paper
• Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03/87 and 04/89.

  1998cited by this paper
• Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia.

  1998cited by this paper
• Intermediate Dose Methotrexate Is as Effective as High Dose Methotrexate in Preventing Isolated Testicular Relapse in Childhood Acute Lymphoblastic Leukemia

  1998cited by this paper
• Prevention of CNS recurrence in childhood ALL: Results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials

  1998cited by this paper
• Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy.

  1998cited by this paper
• Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity.

  1997cited by this paper
• Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups.

  1997cited by this paper
• Early response to therapy and outcome in childhood acute lymphoblastic leukemia

  1997cited by this paper
• Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.

  1996cited by this paper
• Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome. Berlin-Frankfurt-Münster Relapse Study Group.

  1996cited by this paper
• A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Münster Study Group.

  1996cited by this paper
• Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92.

  1996cited by this paper
• High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group.

  1996cited by this paper
• Cytoreduction and prognosis in acute lymphoblastic leukemia--the importance of early marrow response: report from the Childrens Cancer Group.

  1996cited by this paper
• Cytoreduction and prognosis in childhood acute lymphoblastic leukemia.

  1996cited by this paper
• Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. Medical Research Council Working Party on Childhood Leukaemia.

  1995cited by this paper
• Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica.

  1995cited by this paper
• Good steroid response in vivo predicts a favorable outcome in children with T-cell acute lymphoblastic leukemia. The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP).

  1995cited by this paper
• Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL).

  1995cited by this paper
• Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87.

  1995cited by this paper
• Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia.

  1995cited by this paper
• Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86.

  1994cited by this paper
• Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01.

  1994cited by this paper
• Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial.

  1993cited by this paper
• Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Childrens Cancer Group Study CCG-106.

  1993cited by this paper
• Clinical significance of cytogenetic studies in childhood acute lymphoblastic leukemia: experience of the BFM trials.

  1993cited by this paper
• Treatment of acute lymphoblastic leukemia. 30 years' experience at St. Jude Children's Research Hospital.

  1993cited by this paper
• Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group.

  1992cited by this paper
• Minimal requirements for the diagnosis, classification, and evaluation of the treatment of childhood acute lymphoblastic leukemia (ALL) in the "BFM Family" Cooperative Group.

  1992cited by this paper
• Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients.

  1991cited by this paper
• Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy.

  1991cited by this paper
• Comparative results of two intensive treatment programs for childhood acute lymphoblastic leukemia: The Berlin-Frankfurt-Münster and Dana-Farber Cancer Institute protocols.

  1991cited by this paper
• The immunologic detection of minimal residual disease in acute leukemia.

  1990cited by this paper
• Central nervous system relapse prevention in 1165 standard-risk children with acute lymphoblastic leukemia in five BFM trials.

  1990cited by this paper
• Results and significance of six randomized trials in four consecutive ALL-BFM studies.

  1990cited by this paper
• Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features.

  1990cited by this paper
• Detection of minimal residual disease in acute lymphoblastic leukemia by in vitro amplification of rearranged T-cell receptor delta chain sequences.

  1989cited by this paper
• [Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83)].

  1987cited by this paper
• [Treatment of acute lymphoblastic leukemia in childhood and adolescence: results of the multicenter therapy study ALL-BFM 81].

  1987cited by this paper
• Report and recommendations of the Rome workshop concerning poor-prognosis acute lymphoblastic leukemia in children: biologic bases for staging, stratification, and treatment.

  1986cited by this paper
• Frequency and Clinical Significance of DNA Aneuploidy in Acute Leukemia

  1986cited by this paper
• Failure of late intensification therapy to improve a poor result in childhood lymphoblastic leukemia.

  1984cited by this paper
• Acute lymphoblastic leukemia: current status of therapy in children.

  1984cited by this paper
• [Acute lymphoblastic leukemia therapy study BFM 79/81 in children and adolescents: intensified reinduction therapy for patients with different risk for relapse].

  1982cited by this paper
• [Estimation of tumor cell mass in childhood acute lymphoblastic leukemia: prognostic significance and practical application].

  1982cited by this paper
• Thymic involvement and initial white blood count in childhood acute lymphoblastic leukemia.

  1981cited by this paper
• [The BFM 76/79 acute lymphoblastic leukemia therapy study (author's transl)].

  1981cited by this paper
• [The west-berlin therapy study of acute lymphoblastic leukemia in childhood--report after 6 years (author's transl)].

  1977cited by this paper
• Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group

  1976cited by this paper
• Prevention of central nervous system leukemia by irradiation

  1973cited by this paper
• Evaluation of survival data and two new rank order statistics arising in its consideration.

  1966cited by this paper

• Nelarabine in T-cell acute lymphoblastic leukemia: intracellular metabolism and molecular mode-of-action

  2025cites this paper
• German pediatric intensive care transport registry: study protocol for a prospective multicenter registry

  2025cites this paper
• A review on intrathecal administration of medications for leptomeningeal metastases in solid tumors

  2025cites this paper
• Survival of Children with Acute Lymphoblastic Leukemia with Risk Group–Based Protocol Changes: A Single-Center Experience with 460 Patients over a 20-Year Period

  2024cites this paper
• Treatment of Pediatric Acute Lymphoblastic Leukemia: A Historical Perspective

  2024cites this paper
• A Study to Evaluate the Effectiveness and Safety of Prephase Steroid Treatment before Remission Induction Chemotherapy in Patients with Pediatric Acute Lymphoblastic Leukemia Using Common Data Model-Based Real-World Data: A Retrospective Observational Study

  2024cites this paper
• Screening and interventional strategies for the late effects and toxicities of hematological malignancy treatments in pediatric survivors

  2024cites this paper
• Prognostic relevance of treatment deviations in children with relapsed acute lymphoblastic leukemia who were treated in the ALL-REZ BFM 2002 study

  2024cites this paper
• Prognostic significance of CRLF2 in patients with acute lymphoblastic leukemia: a meta-analysis and systematic review

  2024cites this paper
• Contributions of Pediatric Hematology/Oncology to the Diagnosis, Treatment, and Cure of Acute Lymphoblastic Leukemia: Part 2a (Numbers 11 to 15).

  2024cites this paper
• Cognitive performance and brain volume among survivors of pediatric hematological malignancies: a case–control study

  2024cites this paper
• Targeting autophagy as a therapeutic strategy in pediatric acute lymphoblastic leukemia

  2024cites this paper
• Dasatinib overcomes glucocorticoid resistance in B-cell acute lymphoblastic leukemia

  2023cites this paper
• Effectiveness of levofloxacin in the induction of chemotherapy in high-risk acute lymphoblastic leukaemia in children in a developing country

  2023cites this paper
• Assessment of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia: A Multicenter Study From Turkey

  2022cites this paper
• Integrative medicine during the intensive phase of chemotherapy in pediatric oncology in Germany: a randomized controlled trial with 5-year follow up

  2022cites this paper
• Hypoalbuminemia and not undernutrition predicts high‐dose methotrexate‐induced nephrotoxicity in children with acute lymphoblastic leukemia in resource‐constrained centers

  2022cites this paper
• Reduced Dose Intensity of Daunorubicin During Remission Induction for Low-Risk Patients With Acute Lymphoblastic Leukemia: A Retrospective Cohort Study of the Chinese Children’s Cancer Group

  2022cites this paper
• Combined use of peripheral blood blast count and platelet count during and after induction therapy to predict prognosis in children with acute lymphoblastic leukemia

  2021cites this paper
• Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia

  2021cites this paper
• Overexpression of the GR Riborepressor LncRNA GAS5 Results in Poor Treatment Response and Early Relapse in Childhood B-ALL

  2021cites this paper
• Feasibility of Delivering High-Dose Methotrexate in Adolescent and Adult All Patients: A Retrospective Study

  2021cites this paper
• Prostaglandin E2 stimulates cAMP signaling and resensitizes human leukemia cells to glucocorticoid-induced cell death.

  2021cites this paper
• Outcomes and prognostic factors in adolescents and young adults with ALL treated with a modified BFM-90 protocol.

  2021cites this paper
• The Effects of Immunophenotyping with Flow Cytometry on Prognosis in Acute Lymphoblastic Leukemia

  2021cites this paper
• How the COG is Approaching the High-Risk Patient with ALL: Incorporation of Immunotherapy into Frontline Treatment.

  2020cites this paper
• Comparison of outcomes of children with acute lymphoblastic leukemia treated with BMF protocol across 2 decades

  2020cites this paper
• Solitary serum methotrexate level 36 hours post high‐dose methotrexate: A safe, efficacious, and cost‐effective strategy to monitor methotrexate toxicities in childhood leukemia in resource‐limited centers

  2020cites this paper
• Examining treatment responses of diagnostic marrow in murine xenografts to predict relapse in children with acute lymphoblastic leukaemia

  2020cites this paper
• Clinical Characteristics and Treatment Results of Childhood Acute Lymphoblastic Leukemia in North Macedonia

  2020cites this paper
• Cutting to the Front of the Line: Immunotherapy for Childhood Acute Lymphoblastic Leukemia.

  2020cites this paper
• Sustainable care for children with cancer: a Lancet Oncology Commission.

  2020cites this paper
• Reduced-intensity therapy of pediatric lymphoblastic leukemia: Impact of residual disease early in remission induction.

  2020cites this paper
• High TUBB2A expression in childhood T‐ALL is correlated with the clinical outcome

  2020cites this paper
• Extended Follow-Up of Children with High-Risk Acute Lymphoblastic Leukemia Treated with American and European Protocols-A Clash of Different Ideas

  2020cites this paper
• Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols

  2019cites this paper
• Detailed assessment and risk factor analysis of corticosteroid-induced psychiatric disorders in pediatric, adolescent, and young adult patients undergoing induction or consolidation therapy for hematologic malignancy

  2019cites this paper
• Invasive mucormycosis during treatment for acute lymphoblastic leukaemia—successful management of two life-threatening diseases

  2019cites this paper
• Expression Pattern of Long Non-coding RNA Growth Arrest-specific 5 in the Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia

  2019cites this paper
• A rare subgroup of leukemia stem cells harbors relapse-inducing potential in acute lymphoblastic leukemia.

  2019cites this paper
• Reduced vs. standard dose native E. coli-asparaginase therapy in childhood acute lymphoblastic leukemia: long-term results of the randomized trial Moscow–Berlin 2002

  2019cites this paper
• Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331.

  2019cites this paper
• Predictors and outcomes associated with hydroxyurea sensitivity in acute myeloid leukemia patients with high hyperleukocytosis

  2019cites this paper
• TP53, ETV6 and RUNX1 germline variants in a case series of patients developing secondary neoplasms after treatment for childhood acute lymphoblastic leukemia

  2019cites this paper
• Glucocorticoids attenuate the sensitivity of glucocorticoid-resistant lymphoid cells to doxorubicin via reduction in OCTN2

  2019cites this paper
• Prednisolone Prophase for a Week Versus Upfront Multiagent Chemotherapy in Childhood Acute Lymphoblastic Leukemia: An Analysis With Reference to Induction Mortality in a Developing Country

  2019cites this paper
• Long-term follow up of pediatric Philadelphia positive acute lymphoblastic leukemia treated with the EsPhALL2004 study: high white blood cell count at diagnosis is the strongest prognostic factor

  2018cites this paper
• Pharmacogenomic Markers of Glucocorticoid Response in The Initial Phase of Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia

  2018cites this paper
• Metabolic reprogramming of acute lymphoblastic leukemia cells in response to glucocorticoid treatment

  2018cites this paper
• Small-fiber neuropathy and pain sensitization in survivors of pediatric acute lymphoblastic leukemia.

  2018cites this paper
• A semantics-oriented computational approach to investigate microRNA regulation on glucocorticoid resistance in pediatric acute lymphoblastic leukemia

  2018cites this paper
• Long‐term results of the risk‐stratified treatment of childhood acute lymphoblastic leukemia in China

  2018cites this paper
• Early bacterial and fungal infection in children receiving allogeneic stem cell transplantation for acute lymphoblastic leukemia in Argentina

  2018cites this paper
• Phase II/III study in children and adolescents with newly diagnosed B-cell precursor acute lymphoblastic leukemia: protocol for a nationwide multicenter trial in Japan

  2018cites this paper
• Cost-utility of Protocols of BFM-ALL and UK-ALL for Treatment of Children with Acute Lymphoblastic Leukemia in Iran

  2018cites this paper
• Prognostic value of the response to prednisone for children with acute lymphoblastic leukemia: a meta-analysis.

  2018cites this paper
• Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial.

  2018cites this paper
• Development and application of a rapid and sensitive genotyping method for pharmacogene variants using the single-stranded tag hybridization chromatographic printed-array strip (STH-PAS).

  2018cites this paper
• Association Between N363S and BclI Polymorphisms of the Glucocorticoid Receptor Gene (NR3C1) and Glucocorticoid Side Effects During Childhood Acute Lymphoblastic Leukemia Treatment

  2017cites this paper
• Outcome and Clinical Significance of Immunophenotypic Markers Expressed in Different Treatment Protocols of Pediatric Patients With T‐ALL in Developing Countries

  2017cites this paper
• High hyperdiploid acute lymphoblastic leukemia (ALL)—A 25‐year population‐based survey of the Austrian ALL‐BFM (Berlin‐Frankfurt‐Münster) Study Group

  2017cites this paper
• Long-term Results of the Risk-adapted Treatment for Childhood B-Cell Acute Lymphoblastic Leukemia: Report From the Japan Association of Childhood Leukemia Study ALL-97 Trial

  2017cites this paper
• Current challenges and opportunities in treating adult patients with Philadelphia‐negative acute lymphoblastic leukaemia

  2017cites this paper
• Coagulation profile during induction chemotherapy in childhood acute lymphoblastic leukemia

  2017cites this paper
• Treatment for childhood acute lymphoblastic leukemia in Taiwan: Taiwan Pediatric Oncology Group ALL‐2002 study emphasizing optimal reinduction therapy and central nervous system preventive therapy without cranial radiation

  2017cites this paper
• Prognostic factors and treatment of pediatric acute lymphoblastic leukemia

  2017cites this paper
• Central nervous system involvement in acute lymphoblastic leukemia is mediated by vascular endothelial growth factor.

  2017cites this paper
• Trends and territorial inequalities of incidence and survival of childhood leukaemia and their relations to socioeconomic status in Hungary, 1971–2015

  2017cites this paper
• Acute and late toxicities of pirarubicin in the treatment of childhood acute lymphoblastic leukemia: results from a clinical trial by the Japan Association of Childhood Leukemia Study

  2017cites this paper
• MicroRNA-185-5p restores glucocorticoid sensitivity by suppressing the mammalian target of rapamycin complex (mTORC) signaling pathway to enhance glucocorticoid receptor autoregulation

  2017cites this paper
• Analysis of outcomes and prognostic factors of acute lymphoblastic leukemia patients treated by MCP841 protocol: A regional cancer center experience

  2016cites this paper
• New cellular markers at diagnosis are associated with isolated central nervous system relapse in paediatric B‐cell precursor acute lymphoblastic leukaemia

  2016cites this paper
• Characterization of Rare, Dormant, and Therapy-Resistant Cells in Acute Lymphoblastic Leukemia

  2016cites this paper
• Development and validation of LC-MS/MS assay for the simultaneous determination of methotrexate, 6-mercaptopurine and its active metabolite 6-thioguanine in plasma of children with acute lymphoblastic leukemia: Correlation with genetic polymorphism.

  2016cites this paper
• Minimal Residual Disease and Childhood Leukemia: Standard of Care Recommendations From the Pediatric Oncology Group of Ontario MRD Working Group

  2016cites this paper
• Prednisone and dexamethasone in acute lymphoblastic leukemia in children: which is the better option?

  2016cites this paper
• Assessment of Expression and Prognostic Significance of Interleukin 3 Receptor Alpha Subunit (CD123) in Childhood Acute Lymphoblastic Leukemia

  2016cites this paper
• Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232.

  2016cites this paper
• Treatment of children with acute lymphoblastic leukemia with risk group based intensification and omission of cranial irradiation: A Korean study of 295 patients

  2016cites this paper
• SARI, a novel target gene of glucocorticoid receptor, plays an important role in dexamethasone-mediated killing of B lymphoma cells.

  2016cites this paper
• NKX2‐5, SIL/TAL and TLX3/HOX11L2 expression in Egyptian pediatric T‐cell acute lymphoblastic leukemia

  2016cites this paper
• Cost-Analysis of Treatment of Pediatrics Acute Lymphoblastic Leukemia Based on ALL-BFM Protocol

  2016cites this paper
• Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235

  2015cites this paper
• Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia

  2015cites this paper
• Susceptibility to 6‐MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia

  2015cites this paper
• Prognostic significance of cytokine receptor-like factor 2 alterations in acute lymphoblastic leukemia: a meta-analysis

  2015cites this paper
• Improved outcome for children and adolescent with acute lymphoblastic leukemia in the first decade of the 21st century: A report from the Slovak Republic.

  2015cites this paper
• Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer.

  2015cites this paper
• Thiopurine methyltransferase and treatment outcome in the UK acute lymphoblastic leukaemia trial ALL2003

  2015cites this paper
• The Survival of Childhood Leukemia and its Related factors in Kerman, Iran

  2015cites this paper
• Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study

  2015cites this paper
• PEGylated Biopharmaceuticals

  2015cites this paper
• Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial.

  2015cites this paper
• The Survival Rate of Childhood Leukemia and Its Related Factors in Kerman, Iran

  2015cites this paper
• Quantitative proteomic analysis reveals maturation as a mechanism underlying glucocorticoid resistance in B lineage ALL and re‐sensitization by JNK inhibition

  2015cites this paper
• Influence of interleukin-15 polymorphism on the survival of adult patients with acute lymphoblastic leukemia in Egypt

  2015cites this paper
• Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells.

  2015cites this paper
• Superior outcome using cyclosporin A alone versus cyclosporin A plus methotrexate for post-transplant immunosuppression in children with acute leukemia undergoing sibling hematopoietic stem cell transplantation

  2015cites this paper
• How I treat acute lymphoblastic leukemia in older adolescents and young adults.

  2015cites this paper
• PRAME gene expression in childhood acute lymphoblastic leukemia: impact on prognosis.

  2014cites this paper